13D Filing: Fountainhead Capital Management Files Update on Vycor Medical Inc (VYCO) Holding

Page 4 of 4

Page 4 of 4 SEC Filing

 
(b)
The Reporting Person has the sole power to vote and dispose of the 181,994 shares of Series D.
 
 
(c)
Except for the transactions described in the Explanatory Note above, the Reporting Person did not effect any transactions in the issuer’s securities within the past 60 days.
 
 
(d)
No other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Reporting Person’s securities.
 
 
(e)
Not applicable.
 
 
Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.
 
Except as described in the Explanatory Note, there are no contracts, arrangements, understandings or relationships (legal or otherwise) among the Reporting Person and any other person with respect to any securities of the issuer, including, but not limited to transfer or voting of any of the securities, finder’s fees, joint ventures, loan or option arrangements, puts or calls, guarantees of profits, division of profits or loss, or the giving or withholding of proxies.
 
Item 7. Material to be Filed as Exhibits.
 
None
 
SIGNATURES
 
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
 
Dated: February 15, 2016
   
     
 
By:
/s/ Mark Andrews
   
Name: Mark Andrews, for and on behalf of
Berwin Limited, Director
     
     
 
By:
/s/ Eileen O’Shea
   
Name: Eileen O’Shea, for and on behalf of
Moulton Limited, Director
 
 
 


Follow Vycor Medical Inc (OTCMKTS:VYCO)

Page 4 of 4